Morphological changes after combined administration of isoproterenol and K+,Mg2+-aspartate as a physiological Ca2+ antagonist

Recent Adv Stud Cardiac Struct Metab. 1975:6:75-84.

Abstract

The possibility of prevention of isoproterenol (ISO)-induced morphological changes by Ca2+ antagonists was investigated in the heart muscle of dogs. ISO in a dose of 7 mg/kg caused marked histochemical and electron microscopical necrotic changes. K+, Mg2+ aspartate (K,Mg-ASP) administered alone in a dose of 100 mg/kg changed slightly almost all cell components. K,Mg-ASP treatment applied prior to administration of ISO after 24 hours resulted in an improvement of the ultrastructure, which generally exhibited marked restoration resembling metabolic regeneration and/or enhanced metabolic activity.

MeSH terms

  • Animals
  • Aspartic Acid / therapeutic use
  • Calcium / antagonists & inhibitors
  • Cardiomyopathies / chemically induced
  • Cardiomyopathies / pathology*
  • Cardiomyopathies / prevention & control
  • Dogs
  • Glycogen / metabolism
  • Isoproterenol / antagonists & inhibitors
  • Isoproterenol / pharmacology*
  • Magnesium / pharmacology
  • Magnesium / therapeutic use*
  • Male
  • Myocardium / enzymology
  • Myocardium / metabolism
  • Oxidoreductases / metabolism
  • Potassium / pharmacology
  • Potassium / therapeutic use*
  • Time Factors

Substances

  • Aspartic Acid
  • Glycogen
  • Oxidoreductases
  • Magnesium
  • Isoproterenol
  • Potassium
  • Calcium